ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2014 Financial Results
July 18 2014 - 6:30AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops novel anticancer therapeutics using its antibody-drug
conjugate (ADC) technology, today announced that the Company will
host a conference call at 8:00 a.m. ET on Friday, August 1, 2014,
to discuss ImmunoGen's financial results for the three-month period
and fiscal year ended June 30, 2014 and its guidance for its 2015
fiscal year. Management also will provide an update on the
Company.
To access the live call by phone, dial 913-905-3226; the
conference ID is 2600176. The call also may be accessed through the
Investor Information section of the Company's website,
www.immunogen.com. Following the live webcast, a replay of the call
will be available at the same location through August 15, 2014.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The
Company’s ADC technology uses tumor-targeting antibodies to deliver
an ImmunoGen cell-killing agent specifically to cancer cells; the
Company has also developed antibodies with anticancer activity of
their own. The first product approved with ImmunoGen’s ADC
technology is Roche’s Kadcyla®. ImmunoGen has three wholly owned
product candidates in clinical testing with additional compounds in
the clinic through the Company’s partnerships with Amgen, Bayer
HealthCare, Biotest and Sanofi. More information about ImmunoGen
can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, Inc., a member
of the Roche Group.
For Investors:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.comorFor Media:Pure Communications,
Inc.Dan Budwick, 973-271-6085
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024